GlassScriptPhysician profile
Derek A Cooze
NPI 1710937701
$8,143.12
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,231 · 2020: $2,093 · 2021: $2,552 · 2022: $267.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $986.75 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $873.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $779.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $746.52 | 2019-2022 | |
| Abbvie INC. | $567.16 | 2019-2022 | |
| Amgen INC. | $524.03 | 2019-2022 | |
| Allergan, INC. | $475.16 | 2019-2021 | |
| Pfizer INC. | $323.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.02 | 2019-2022 | |
| Amarin Pharma, INC. | $258.48 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $232.54 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $217.96 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $198.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $196.14 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $188.05 | 2019 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Cooze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.